ESR1 and breast carcinoma: BT-474 cells also had no change in radiosensitisation with 0.5–2.0 μM apalutamide (rER: 0.96–0.98, Supplementary Fig. 3C), 0.5–2.0 μM darolutamide (rER: 0.94–0.97, Supplementary Fig. 3G) or 0.5–2.5 μM seviteronel (rER: 0.90–0.98, Supplementary Fig. 3J), further suggesting that though these inhibitors have structural and potential functional differences, each is insufficient under these conditions to induce radiosensitisation of AR+/ER+ breast cancer cell lines in vitro.